PARP1 and neutropenia: The results also showed that many more events occurred in the niraparib group in the PRIMA [22] trial (n = 484) than in other RCTs using other types of PARP inhibitors (grade ≥ 3: thrombocytopenia, 41.7%; anemia, 40.0%; and neutropenia, 20.5%; Online Resource Table 5).